A pahse 2 clinical study of levosimendan to treat patients with Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)

Next Previous
Trial Profile

A pahse 2 clinical study of levosimendan to treat patients with Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Pulmonary hypertension
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Tenax Therapeutics

    • Most Recent Events

    • 04 Apr 2018 According to a Tenax Therapeutics media release, the company will finalize trial protocol for IND submission and continue preparations to start of the trial by late June or July.
    • 04 Apr 2018 According to a Tenax Therapeutics media release, the FDA agreed that the new Phase 2 clinical protocol can be submitted under the existing IND, and supported the study design and endpoints for demonstrating proof-of-concept in PH-HFpEF patients.
    • 01 Mar 2018 According to a Tenax Therapeutics media release, the company anticipates to begin this trial in the later part of Q2 0218.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top